News Aug 05, 2026
Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization
Porton Advanced Solutions Ltd. has officially been granted a Drug Manufacturing License (Class C) by the National Medical Products Administration (NMPA). This milestone qualifies Porton Advanced to undertake commercial contract manufacturing for Cell and Gene Therapy (CGT) products, extending its CDMO services from process development and clinical production through to the commercialization stage.
News Jul 08, 2026
Porton Advanced’s UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance
Porton Advanced’s UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance
News Jul 03, 2026
Porton Delivers Dual-Payload ADC IND, Advancing Next-generation Conjugate Drug Development
Porton One-stop Biologics and Conjugates CDMO Platform successfully completed the full-cycle delivery of process development and GMP IND clinical sample manufacturing for a dual-payload ADC.
News Jul 02, 2026
Porton Highlights Integrated CDMO Capabilities at BIO International Convention 2026 and Celebrates Porton J-STAR's 30th Anniversary
Porton Highlights Integrated CDMO Capabilities at BIO International Convention 2026 and Celebrates Porton J-STAR’s 30th Anniversary
News Jun 25, 2026
Porton Concludes Productive Presence at CPHI China 2026
Porton Pharma Solutions Ltd. (“Porton”) wrapped up a productive three-day presence at CPHI China 2026, which was held from June 16 to 18 at the Shanghai New International Expo Centre.
News Apr 03, 2026
Porton & Pliant Joint Publication in ACS Catalysis
Process Chemistry and Catalysis & Enabling Technology Teams Reported a Novel Breakthrough in Catalytic Transformation
NewslettersMar 31, 2026
Porton Newsletter - March 2026 Recap
Porton Newsletter - March 2026 Recap
News Mar 22, 2026
Porton and Jianxiang Forge Strategic Partnership to Build a New High Ground for Large-scale Peptide Drug Manufacturing
Porton and Jianxiang partner to deliver integrated peptide CDMO services from development to commercial manufacturing, offering scalable, compliant solutions for global clients.
News Mar 03, 2026
Porton Wins “2025 Best CRO” Award from Daewoong Pharma
Daewoong Pharma highly recognized Porton’s contributions to its drug development through active cooperation based on Porton’s excellent capabilities and expertise.
